The conundrum of human immune system "senescence"
- PMID: 32949594
- PMCID: PMC7494491
- DOI: 10.1016/j.mad.2020.111357
The conundrum of human immune system "senescence"
Abstract
There is a great deal of debate on the question of whether or not we know what ageing is (Ref. Cohen et al., 2020). Here, we consider what we believe to be the especially confused and confusing case of the ageing of the human immune system, commonly referred to as "immunosenescence". But what exactly is meant by this term? It has been used loosely in the literature, resulting in a certain degree of confusion as to its definition and implications. Here, we argue that only those differences in immune parameters between younger and older adults that are associated in some definitive manner with detrimental health outcomes and/or impaired survival prospects should be classed as indicators of immunosenescence in the strictest sense of the word, and that in humans we know remarkably little about their identity. Such biomarkers of immunosenescence may nonetheless indicate beneficial effects in other contexts, consistent with the notion of antagonistic pleiotropy. Identifying what could be true immunosenescence in this respect requires examining: (1) what appears to correlate with age, though generality across human populations is not yet confirmed; (2) what clearly is part of a suite of canonical changes in the immune system that happen with age; (3) which subset of those changes accelerates rather than slows aging; and (4) all changes, potentially population-specific, that accelerate agig. This remains an immense challenge. These questions acquire an added urgency in the current SARS-CoV-2 pandemic, given the clearly greater susceptibility of older adults to COVID-19.
Keywords: Cytomegalovirus; Human immunosenescence; Inflammageing; Longitudinal study; Vaccination.
Copyright © 2020 Elsevier B.V. All rights reserved.
Conflict of interest statement
AAC is founder and CSO at Oken Health.
S.C.C. declares that he has consulted for and has received honoraria, test products and/or research funding from Abitec, Accera, Bulletproof, Servier and Nestlé Health Science, is the founder of Senotec and is co-inventor on a patent for an medium chain triglyceride formulation.
OTN is supported by a fellowship on research productivity (grant 303540/2019-2) from CNPq/Brazil.
References
-
- Adriaensen W., Pawelec G., Vaes B., Hamprecht K., Derhovanessian E., van Pottelbergh G. CD4:8 ratio above 5 is associated with all-cause mortality in CMV-seronegative very old women: results from the BELFRAIL study. J. Gerontol. A Biol. Sci. Med. Sci. 2017;72(9):1155–1162. doi: 10.1093/gerona/glw215. PubMed PMID: 27927759. - DOI - PubMed
-
- Aiello A., Farzaneh F., Candore G., Caruso C., Davinelli S., Gambino C.M. Immunosenescence and its hallmarks: how to oppose aging strategically? A review of potential options for therapeutic intervention. Front. Immunol. 2019;10:2247. doi: 10.3389/fimmu.2019.02247. PubMed PMID: 31608061; PubMed Central PMCID: PMCPMC6773825. - DOI - PMC - PubMed
-
- Akbar A.N., Reed J.R., Lacy K.E., Jackson S.E., Vukmanovic-Stejic M., Rustin M.H. Investigation of the cutaneous response to recall antigen in humans in vivo. Clin. Exp. Immunol. 2013;173(2):163–172. doi: 10.1111/cei.12107. PubMed PMID: 23607634; PubMed Central PMCID: PMCPMC3722916. - DOI - PMC - PubMed
-
- Alam I., Goldeck D., Larbi A., Pawelec G. Aging affects the proportions of T and B cells in a group of elderly men in a developing country--a pilot study from Pakistan. Age (Dordr) 2013;35(5):1521–1530. doi: 10.1007/s11357-012-9455-1. PubMed PMID: 22810104; PubMed Central PMCID: PMCPMC3776124. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
